WHO ICTRP trial
Phase I clinical study on the safety of HER2-specific chimeric antigen receptor…
JPRN-jRCT2033220088 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2033220088 |
|---|---|
| Public title | Phase I clinical study on the safety of HER2-specific chimeric antigen receptor (CAR) gene-modified T cell therapy |
| Scientific title | Phase I clinical study on the safety of HER2-specific chimeric antigen receptor (CAR) gene-modified T cell therapy - BP2301-01 |
| Primary sponsor | Yozo Nakazawa |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 1 |
| Conditions | HER2 positive osteosarcoma/soft tissue sarcoma and gynecologic malignancy |
| Interventions | Administration of CAR-T cells produced from eripheral blood. The target dose assigned to the subject as CAR-expressing T cells (range: 8.3 x 10^5 cells/kg or 2.7 x 10^6 cells/kg) is intravenously infused. |
| Registration date | May 25, 2022 |
| Target size | 12 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: